John W. Smither - 27 Dec 2023 Form 4 Insider Report for Applied Molecular Transport Inc.

Role
Director
Signature
/s/ Brandon Hants Attorney-in-Fact for John W. Smither
Issuer symbol
N/A
Transactions as of
27 Dec 2023
Net transactions value
$0
Form type
4
Filing time
28 Dec 2023, 17:38:19 UTC
Previous filing
14 Sep 2023
Next filing
29 Dec 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -60,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 60,000 $8.01 Direct F1
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -20,000 -100% $0.000000* 0 24 May 2022 Common Stock 20,000 $3.13 Direct F1
transaction AMTI Stock Option (Right to Buy) Disposed to Issuer $0 -20,000 -100% $0.000000* 0 27 Dec 2023 Common Stock 20,000 $0.3400 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John W. Smither is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated as of September 21, 2023 (the "Merger Agreement"), by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc. and the Issuer, at the effective time of the merger, each outstanding option with an exercise price of $0.40 or more was cancelled effective as of the closing.
F2 Pursuant to the terms of the Merger Agreement, this option was exchanged for an option covering 2,662 shares of Cyclo Common Stock.